A SPAC deal with RA Capital–sponsored RACC is expected to yield ~$175 million gross, including a fully backstopped trust and PIPE/SAFE financing, with closing targeted by end of 2026. Rugonersen, an ...
Within your prior big pharma employers, AI is now a core competitive capability as it has shortened target identification and optimized molecule design. As building world-class AI drug-discovery ...
Project Trialblazer prioritizes reducing IND review timelines, but its impact on sponsor behavior may be limited when ...
In today's Pharmaceutical Executive Daily, BioMarin and n-Lorem Foundation partner on the first disease-targeted therapy for the recently identified ReNU syndrome, a trio of biotech financings advance ...
Pharmaceutical Executive spoke with Dr. Richard Graham, chairman and co-founder of TruTechnologies about FDA’s new program ...
FDA authorization covers adults and children ≥6 years (≥20 kg) for once-daily centanafadine ER, positioned as a CNS stimulant with a first-in-class NDSRI mechanism. Evidence derived from four pivotal ...
This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...
Specialty pharma launches depend heavily on data from outside the organization. Distributors, third-party logistics providers ...
Since then, that mindset has continued to grow at AbbVie.
In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a collaboration with QuantumCell ApS worth more than $2.2 billion for global rights to its Neurostore platform including ...
Indication includes adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, for LDL-C ...
Leavitt Partners' Julie Tierney and RC Resolve, part of Real Chemistry's Maggie Farley, look at which pharma policies could actually pass — and how companies should talk to stakeholders if pricing or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results